Under fire for pricing and more, PhRMA boosts lobbying spend 30% in 2017

PhRMA increased its lobbying expenses by 29% in 2017, according to disclosure forms. (Pixabay)

As the drug industry took heat from Trump in 2017 for "getting away with murder," among other criticisms, its lobbyists were busy behind the scenes working with officials to protect it, according to lobbying disclosure forms. In all, the industry's biggest lobby group, PhRMA, boosted its spending by 29.6% last year.

PhRMA spent the most on lobbying—$7.98 million—in the first quarter, according to the disclosure documents. Its efforts ranged from patent issues, Bayh-Dole march-in rights, importation, Medicare price negotiations and more. 

The first quarter of 2017 was also when then President-elect Donald Trump blasted the industry for "getting away with murder" and for its influence in Washington.  

“Pharma has a lot of lobbies, lobbyists and a lot of power," he said at the time. "There is very little bidding on drugs.”

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Drug stocks fell immediately, but over time, industry concerns about government intervention on prices have eased.  

RELATED: Trump to pharma: You're 'getting away with murder,' and I'm the one to stop it 

Despite the tough talk, much of the Trump administration's actions on drug pricing have been focused around increasing competition through the FDA rather than on a larger regulatory overhaul. All told in 2017, PhRMA spent $25.43 million lobbying, according to its disclosure forms, compared to $19.62 million in 2016.  

In response to an intense focus on drug prices over the last several years, many drugmakers have committed to limiting their price increases, while the industry has also tried to shift the spotlight to growing rebates and discounts paid to payers.

Just this month, two biopharma CEOs offered contrasting perspectives on the pricing issue at the J.P. Morgan Healthcare Conference. Merck CEO Ken Frazier said he doesn't expect "any kind of significant jump" in pricing pressure from payers or public agencies, while Eli Lilly CEO David Ricks said the industry should get involved in moderating prices or it might face more pushback. 

With "people who are in power who understand that tricky balance, that fragile balance between reward for innovation and access," Ricks said it's important for the industry to act on ensuring affordability.

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.